 This trial is a randomized, double blind, placebo-controlled trial to determine the safety, tolerability and pharmacokinetics of TMC435350 after single and multiple oral doses taken by healthy non-Hepatitis C Virus infected non-HCV participants, followed by an open label repeated doses taken by 6 HCV-genotype 1 infected participants non-placebo controlled. The single dose escalation part of the trial will consist of 6 sessions Sessions Ia to VIa and will include 2 panels of 9 healthy non-HCV infected participants each Panels 1 and 2. The dose of the test drug will be consecutively escalated. Doses of 50 mg, 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg of TMC435350 or placebo will be administered as a single oral administration alternating over the 2 panels. In each session, 6 participants will receive active treatment and 3 participants will receive placebo after a breakfast. The treatment schedule will ensure that over 3 sessions each particpant will receive active treatment twice and placebo once. There is a washout period of at least 10 days between consecutive TMC435350 or placebo dosings within each panel. Participants of Panel 1 will have an additional session to investigate food effect: a single dose of TMC435350 will be tested in fasted conditions Session VIIa. Food effect will be investigated for the 200 mg dose in Panel 1, unless the the available concentration of the drug in the blood and safety data from previous sessions prove unnecessary. Multiple dosing will be started when Sessions Ia single dose of 50 mg, IIa single dose of 100 mg and IIIa single dose of 200 mg are found to be safe and tolerable. The multiple dose escalation part of the trial will consist of 4 consecutive sessions Sessions Ib to IVb in 4 panels of 9 healthy non-HCV infected participants each Panels 3, 4, 5 and 6. In each session, 6 participants will receive active treatment and 3 participants will receive placebo. TMC435350 or placebo will be administered during 5 consecutive days. As a potential food effect is not yet known, administration will be after a meal. Treatment is anticipated to be twice daily with doses of 50 mg, 100 mg, 200 mg and 400 mg. The available concentration of the drug in the blood will be determined up to 72 hours after the first dose, in case a single dose of TMC435350 is given in Sessions Ia to VIIa and, if performed, Session VIIIa. In case of multiple dosing in Sessions Ib to IVb, full pharmacokinetic profiles of TMC435350 will be determined for the first dosage interval e.g. up to 24 hours after the first dose for a b.i.d. regimen and up to 72 hours after the last dose. Safety and tolerability will be evaluated continuously and documented safety report, with 24-hours interim PK data after the last dose, before stepping up to the next dose and between each session. After completion of the healthy participant sessions, an open label session Ic in HCV genotype 1 infected participant will be added. The trial population Panel 7 will include 6 male or female, non-responder HCV-genotype 1 infected participants with an HCV viral load of at least 50000 IUmL. These participants will be treated as Panel 7 with follow-up visits, after the 5 day dosing period. One dose regimen will be selected which was shown to be safe in healthy participants and as close as possible to a maximum tolerated dose, which will be administered for 5 days. In addition to drug safety and PK parameters, viral loads will be determined in plasma. 